The University of Chicago Header Logo

Connection

Michael Becker to Chronic Disease

This is a "connection" page, showing publications Michael Becker has written about Chronic Disease.
Connection Strength

0.645
  1. Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 2015; 31 Suppl 2:9-14.
    View in: PubMed
    Score: 0.096
  2. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014 Mar 04; 16(2):R60.
    View in: PubMed
    Score: 0.091
  3. Long-term management of gout: nonpharmacologic and pharmacologic therapies. Rheum Dis Clin North Am. 2014 May; 40(2):357-74.
    View in: PubMed
    Score: 0.090
  4. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013 Sep 01; 72(9):1469-74.
    View in: PubMed
    Score: 0.083
  5. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011; 14(1):10-5.
    View in: PubMed
    Score: 0.072
  6. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014 Dec; 20(8):427-32.
    View in: PubMed
    Score: 0.024
  7. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26; 15(5):R137.
    View in: PubMed
    Score: 0.022
  8. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17; 306(7):711-20.
    View in: PubMed
    Score: 0.019
  9. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011 Jul; 38(7):1452-7.
    View in: PubMed
    Score: 0.019
  10. Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol. 2011 Jul; 38(7):1458-61.
    View in: PubMed
    Score: 0.019
  11. Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology? J Rheumatol. 2011 Jul; 38(7):1462-6.
    View in: PubMed
    Score: 0.019
  12. Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol. 2011 Jul; 38(7):1467-70.
    View in: PubMed
    Score: 0.019
  13. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis. 2008 Jun; 67(6):888-91.
    View in: PubMed
    Score: 0.015
  14. Outcome evaluations in gout. J Rheumatol. 2007 Jun; 34(6):1381-5.
    View in: PubMed
    Score: 0.014
  15. Outcome measures for acute and chronic gout. J Rheumatol. 2005 Dec; 32(12):2452-5.
    View in: PubMed
    Score: 0.013
  16. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003 Aug; 9(8):505-11.
    View in: PubMed
    Score: 0.011
  17. Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations. Gastroenterology. 2002 Oct; 123(4):1020-5.
    View in: PubMed
    Score: 0.010
  18. Mutations of the serine protease inhibitor, Kazal type 1 gene, in patients with idiopathic chronic pancreatitis. Am J Gastroenterol. 2002 May; 97(5):1133-7.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.